Is Hematology Having an Identity Crisis?
Drs. Naik and Lee discuss the recent hematology workforce study and its significance for the field.
Diagnostic Algorithm Reduces the Need for Radiation Exposure to Rule Out Pulmonary Embolism in Pregnant Women
Dr. Linkins looks at using algorithms based on clinical prediction rules and blood testing for D-dimer level to diagnose pulmonary embolism (PE), thus reducing the need for
A 3-part series of personalized podcasts for the trainee, PhD, and hemostasis/thrombosis communities will provide invaluable information to help attendees make the most of the 2019 ASH Annual Meeting.
Drs. Prajwal Boddu and Amer Zeidan discuss therapy-related myeloid disease after autoimmune illness.
Drs. Arnold and Teachey review a trial observing self-inactivating-lentiviral gene therapy in eight consecutive male infants newly diagnosed with X-linked severe combined immunodeficiency and no matched sibling donor.
July/August 2019Volume 16, Issue 4
View all Features articles
View all Diffusion articles
Dr. Silverstein stresses the important role different people, including staff, volunteers, and board and committee members, play in moving the Society forward and furthering its mission.
View all president's column articles
View all Ask the Hematologist articles
View all Clinical Trials Corner articles
View all Mini Review articles
ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.
ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.
ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.
In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology